| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
TP-3654 is a novel and potent inhibitor of Pim-1 and Pim-3 (proviral integration site for moloney murine leukemia virus) kinase that is potentially useful for the treatment of various cancers such as prostate cancer, acute myeloid leukemia, multiple sclerosis and psoriasis. As a second-generation PIM inhibitor, TP-3654 displays submicromolar activity with Ki values of 5 and 42 nM for Pim-1 and Pim-3, respectively in pharmacodynamic biomarker modulation, cell proliferation studies, and colony formation assays using the UM-UC-3 bladder cancer cell line. TP-3654 demostrates favorable human ether-à-go-go-related gene and cytochrome P450 inhibition profiles compared with the first-generation PIM inhibitor, SGI-1776, and exhibits oral bioavailability. In vivo xenograft studies using a bladder cancer cell line show that PIM kinase inhibition can reduce tumor growth, suggesting that PIM kinase inhibitors may be active in human urothelial carcinomas.
| Targets |
Pim-1 (Ki=5 nM); Pim-2 (Ki=239 nM); Pim-3 (Ki=42 nM)
|
|---|---|
| ln Vitro |
In the PIM-1/BAD overexpression system, TP-3654 exhibits strong PIM-1 specific cellular action with an average EC50 of 67 nM. TP-3654 therapy lowers phospho-BAD levels in vitro using UM-UC-3 bladder cancer cell line. T24 and UM-UC3 cell colony growth is inhibited by TP-3654, indicating that PIM-1 is required for the proliferation of these two cell lines[1].
|
| ln Vivo |
With no appreciable changes in body weight or gross adverse toxicity, oral dosage of 200 mg/kg TP-3654 significantly reduces both UM-UC-3 and PC-3 tumor growth as measured by volume (caliper) and final tumor weight[1].
|
| Cell Assay |
TP-3654 is tested against 336 kinases at 10 μM ATP concentration. IC50 determinations of PI3K and all inhibited kinases are performed using 10-dose, three-fold serial dilutions of TP-3654 starting with 10 μM at Km ATP concentrations for each kinase.[1].
|
| Animal Protocol |
The study involved mice with tumors measuring 100-200 mm3 and randomized to receive oral dosing of TP-3654 or vehicle control every day for 5 days, with 2 days off for 18-21 days, and tumor volumes and body weights determined weekly[1].
|
| References |
[1]. Foulks JM, et al. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. Neoplasia. 2014 May;16(5):403-12
|
| Molecular Formula |
C22H25F3N4O
|
|
|---|---|---|
| Molecular Weight |
418.46
|
|
| CAS # |
1361951-15-6
|
|
| Related CAS # |
1418143-09-5 (HCl);1361951-15-6;
|
|
| SMILES |
CC(C)(C1CCC(CC1)NC2=NN3C(=NC=C3C4=CC(=CC=C4)C(F)(F)F)C=C2)O
|
|
| InChi Key |
XRNVABDYQLHODA-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C22H25F3N4O/c1-21(2,30)15-6-8-17(9-7-15)27-19-10-11-20-26-13-18(29(20)28-19)14-4-3-5-16(12-14)22(23,24)25/h3-5,10-13,15,17,30H,6-9H2,1-2H3,(H,27,28)
|
|
| Chemical Name |
2-[4-[[3-[3-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]amino]cyclohexyl]propan-2-ol
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~84 mg/mL ( 200.73 mM）
Water: <6 mg/mL Ethanol: Insoluble |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.97 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.97 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.97 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3897 mL | 11.9486 mL | 23.8971 mL | |
| 5 mM | 0.4779 mL | 2.3897 mL | 4.7794 mL | |
| 10 mM | 0.2390 mL | 1.1949 mL | 2.3897 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03715504 | Completed | Drug: TP-3654 | Advanced Solid Tumors | Sumitomo Pharma Oncology, Inc. | April 16, 2019 | Phase 1 |
| NCT04176198 | Myelofibrosis | Drug: TP-3654 | Advanced Solid Tumors | Sumitomo Pharma Oncology, Inc. | December 16, 2019 | Phase 2 |
PIM-1 overexpression increases cellular pBAD levels, whereas TP-3654 decreases pBAD levels and PIM-1–driven xenografts.Neoplasia.2014 May;16(5):403-12. |
|---|
Validation of PIM-1 in solid tumor modelsin vitro.Neoplasia.2014 May;16(5):403-12. |
TP-3654 inhibits the growth of established solid tumor xenografts.Neoplasia.2014 May;16(5):403-12. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
